April 17, 2012
Another Amyloid Tracer Shows Promise in Alzheimer’s
On the heels of the US Food and Drug Administration (FDA) approval of the amyloid tracer agent florbetapir (Amyvid, Eli Lilly), another biomarker is showing promise in detecting beta-amyloid deposition in the brains of living patients…Asked for his opinion, David Knopman, MD, Department of Neurology, Mayo Clinic, Rochester, Minnesota, said he found the accuracy of […]
Tags: Dr. David Knopman, florbetapir, Food and Drug Administration